Longevity whirlwind: plasma exchange, gene therapy, and Liz Parrish doing all of it first

Longevity whirlwind: plasma exchange, gene therapy, and Liz Parrish doing all of it first

The latest longevity circuit sounds less like a conference and more like a live-fire lab meeting. Dr. Mike's newsletter recaps a whirlwind of gatherings, a new therapeutic plasma exchange clinic, and AI-driven plans bundling blood pressure control, hormonal therapies, and gene therapy. The standout: Liz Parrish, who pioneered gene therapy on herself in 2015 and has spent the last 11 years targeting genes tied to muscle mass, telomere length, and brain function.

Gobble's Take: The field keeps trying to outrun aging — but half the sprint is still figuring out which ideas are science and which are just very expensive optimism.

Source: Longevity Whirlwind - Dr Mike's Newsletter

Longevity medicine: same playbook, bigger invoice

This piece doesn't whisper. It argues that "longevity medicine" is a rebrand cycle, and that the evidence-based core is just good primary care. Everything else gets the side-eye: rapamycin scripts for healthy 40-year-olds, IV NAD+ drips, non-FDA-approved peptides, $600 epigenetic clocks, stem cell tourism. It lands the point with a Nature Biotechnology quote: drug candidates including anti-inflammatory drugs, sirtuin activators, senolytics, NAD+ precursors, metformin, and rapamycin have not yet been shown to slow aging or age-related disease onset.

Gobble's Take: When the invoice grows faster than the evidence, you're looking at a brand strategy wearing a lab coat.

Source: Is Longevity Medicine Is the Latest Marketing Buzzword?

The new longevity playbook: biomarkers, epigenetics, and N-of-1 everything

The Longevity Digest admits the field moves too fast to track — then goes ahead and tracks it anyway. The bigger story isn't any single molecule; it's a shift toward precision longevity built on genomics, transcriptomics, proteomics, metabolomics, and the exposome. CDC Director Jim O'Neill described a $144M ARPA-H initiative to identify and FDA-validate causal biomarkers of aging. Meanwhile, an 8-week dietary and lifestyle program reversed epigenetic age by over three years on the Horvath clock — with methyl-donor foods and polyphenol-rich herbs and spices doing the work, and curcumin, EGCG, rosemary, and urolithin A recast as epigenetic reprogramming agents.

Gobble's Take: The future of longevity looks less like one miracle molecule and more like a very fussy spreadsheet that happens to know your entire biology.

Source: The Longevity Digest 05/12 - 05/18

AI wants to be your longevity coach, your biomarker tracker, and your most persistent nag

This blueprint-style piece makes the case for AI as a full-stack health companion: polygenic risk scores, epigenetic clocks, wearable monitoring, and dashboards that blend genetics with diet, exercise, stress, and environmental exposures. The prevention toolkit runs from dietary changes and targeted supplements to tailored exercise and increased health screenings. Intermittent fasting, stress management, improved sleep hygiene, NAD+ boosters, resveratrol, and spermidine all make the list.

Gobble's Take: The machine doesn't just want your data anymore — it wants to fix your habits before your habits can make a mess.

Source: The Longevity Blueprint: How AI Unlocks the Secrets to Longer Life

In Case You Missed It

Yesterday's top stories:

• The Weight Loss Drug Making Ozempic Look Slow
• Turning Back the Clock: How a 56-Year-Old Reclaimed His Youth
• The Perilous Path to Peptides: A Warning from the Front Lines